Skip to main content
Erschienen in: Reactions Weekly 1/2011

01.11.2011 | Case report

Imatinib

Development of resistance: case report

Erschienen in: Reactions Weekly | Ausgabe 1/2011

Einloggen, um Zugang zu erhalten

Excerpt

An event is serious (FDA MedWatch definition) when the patient outcome is:
  • death
  • life-threatening
  • hospitalisation
  • disability
  • congenital anomaly
  • requires intervention to prevent permanent impairment or damage
Literatur
1.
Zurück zum Zitat Diamantopoulos PT, Athanasiadou A, Papakostas E, Gratsias N, Georgiou G, Mantzourani M, Andreopoulos G, Panagiotidis P, Aessopos A, Meletis J, Viniou N.Translocation t(12;13)(p13;q14) in a patient with imatinib-sensitive MDS/MPD associated with resistance to treatment: Review of the literature. Anti-Cancer Drugs 22: 944-947, No. 9, Oct 2011. Available from: URL: http://dx.doi.org/10.1097/cad.0b013e3283486ca4 - Greece Diamantopoulos PT, Athanasiadou A, Papakostas E, Gratsias N, Georgiou G, Mantzourani M, Andreopoulos G, Panagiotidis P, Aessopos A, Meletis J, Viniou N.Translocation t(12;13)(p13;q14) in a patient with imatinib-sensitive MDS/MPD associated with resistance to treatment: Review of the literature. Anti-Cancer Drugs 22: 944-947, No. 9, Oct 2011. Available from: URL: http://​dx.​doi.​org/​10.​1097/​cad.​0b013e3283486ca4​ - Greece
Metadaten
Titel
Imatinib
Development of resistance: case report
Publikationsdatum
01.11.2011
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2011
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.2165/00128415-201113760-00053

Weitere Artikel der Ausgabe 1/2011

Reactions Weekly 1/2011 Zur Ausgabe

Case report

Bupropion

Case report

Docetaxel

Case report

Hydroxocobalamin

Case report

Etanercept

Case report

Various drugs